National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nintedanib (Vargatef®) indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.

Rapid Review

Commenced Completed Outcome
02/01/2015 10/02/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
03/06/2015  25/03/2016 Reimbursement not Recommended at the Submitted Price.

Summary

February 2017

The HSE has approved reimbursement following confidential price negotiations.